Abcam, ab251159, Anti-MIP-3 beta/CCL19 antibody [EPR7044(2)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal MIP-3 beta/CCL19 antibody. Carrier free. Suitable for WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR7044(2),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, Flow Cyt (Intra)See reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab251159 is the carrier-free version of
ab192877
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MIP-3 beta also known as CCL19 is a chemokine involved in immune responses. It weighs around 11 kDa and is encoded by the CCL19 gene. MIP-3 beta does its function by binding to its receptor CCR7 which is common in lymph nodes and other lymphoid tissues. It recruits and directs the migration of immune cells especially T cells and dendritic cells navigating them towards lymphoid tissues. This makes MIP-3 beta integral in initiating and modulating immune responses.
Biological function summary
MIP-3 beta helps direct cell trafficking within the lymphoid organs. It is not part of a complex but its interaction with the CCR7 receptor is essential for its biological activity. This binding plays a role in the development of secondary lymphoid organs and immune surveillance. Furthermore MIP-3 beta supports the homing of immune cells to appropriate locations impacting both innate and adaptive immune responses.
Pathways
MIP-3 beta is associated with the chemokine signaling pathway and the immune system pathway. Through these pathways it interacts with proteins like CCR7 and other chemokines that regulate leukocyte migration and activation. These pathways ensure local and systemic immune responses are efficiently orchestrated impacting inflammation and immune regulation.
MIP-3 beta has connections to autoimmune diseases like rheumatoid arthritis and cancer. Its deregulation can result in abnormal immune surveillance contributing to the pathology of these conditions. MIP-3 beta regulates immune cell infiltration and any imbalance may also link it to other inflammatory disorders. Relations to proteins such as CCR7 in these conditions emphasize its role in disease pathogenesis and highlight its potential as a therapeutic target.